Gilead Sciences Inc (GILD)

67.71 +0.64  +0.95% NASDAQ Jan 20, 14:19 USD
View Full Chart
Price Chart
View All GILD News

News

View All Events

Events

Date Type Description
02/04/2021 Earnings Gilead Sciences Inc Fourth Quarter Earnings for 2020 Release
02/04/2021 16:30 EST Misc Gilead Sciences Inc Fourth Quarter Earnings Conference Call for 2020
12/14/2020 Dividends Amount: 0.68, Declared Date: Oct 29 2020, Pay Date: Dec 30 2020
10/28/2020 Earnings Gilead Sciences Inc Third Quarter Earnings Result for 2020
10/28/2020 16:30 EDT Misc Gilead Sciences Inc Third Quarter Earnings Conference Call for 2020
09/14/2020 Dividends Amount: 0.68, Declared Date: Jul 30 2020, Pay Date: Sep 29 2020
07/30/2020 16:30 EDT Misc Gilead Sciences Inc Second Quarter Earnings Conference Call for 2020
07/30/2020 Earnings Gilead Sciences Inc Second Quarter Earnings Result for 2020
06/11/2020 Dividends Amount: 0.68, Declared Date: Apr 30 2020, Pay Date: Jun 29 2020
05/06/2020 10:00 PDT Misc Gilead Sciences Inc Annual General Meeting for 2019
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.gilead.com
  • Investor Relations URL: http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-irhome
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Drug Manufacturers - General
  • Equity Style: Large Cap/Value
  • Next Earnings Release: Feb. 04, 2021
  • Last Earnings Release: Oct. 28, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: Dec. 14, 2020
  • Description: Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Top Fund Holders

Symbol Name Weighting
IBB iShares Nasdaq Biotechnology ETF 6.29%
CMLFX American Funds American Mutual 529F 2.98%
MOAT VanEck Vectors Morningstar Wide Moat ETF 2.33%
XLV Health Care Select Sector SPDR® ETF 1.81%
USMV iShares MSCI USA Min Vol Factor ETF 1.43%
RCEEX American Funds Capital Income Bldr R2E 1.40%
VHT Vanguard Health Care ETF 1.31%
RICEX American Funds Invmt Co of Amer R4 1.16%
FWWMX American Funds Washington Mutual 529-F-3 1.08%
VLUE iShares MSCI USA Value Factor ETF 1.02%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.